Literature DB >> 11237130

Anti-insulin antibodies and the natural autoimmune response in systemic lupus erythematosus.

M Lidar1, A Braf, N Givol, P Langevitz, R Pauzner, A Many, A Livneh.   

Abstract

Systemic lupus erythematosus (SLE) is characterized by the finding of ample serum autoantibodies. The role and the origin of many of these antibodies are still obscure. The aim of this work was to study the occurrence of anti-insulin antibodies (AIA) in SLE, and to postulate, based on AIA determination, on the mechanisms involved in the production of some autoantibodies in SLE. IgG and lgM AIA, anti-DNA antibodies (ADA) and anti-tetanus toxoid antibodies (ATA) were determined using ELISA in sera and B-lymphocytes culture media of 24 SLE patients, 10 healthy controls and 19 insulin-dependent diabetes mellitus (IDDM) patients. B- and T-lymphocytes were isolated using Ficoll gradient, depleted of T-cells using cyclosporin A, EBV infected and grown in medium. The frequencies of IgM-AIA and IgG-ADA were higher in SLE patients than in healthy controls (P < 0.02 and P < 0.05, respectively). The rate of IgM-AIA in SLE and IDDM was comparable, while IgG-AIA was significantly less common in SLE than in IDDM (P < 0.05). The prevalence of ATA in SLE patients and healthy controls was similar. These findings increase the spectrum of the humoral autoimmune response in SLE and suggest that part of it (natural autoantibodies) is independent of antigen driven response.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11237130     DOI: 10.1191/096120301669081314

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  5 in total

1.  Lack of anti-insulin, anti-GAD, and anti-IA2 autoantibodies in primary antiphospholipid syndrome.

Authors:  Jozélio Freire de Carvalho; Maria Teresa Correia Caleiro
Journal:  Rheumatol Int       Date:  2011-03-26       Impact factor: 2.631

2.  Elevation of fasting insulin and its association with cardiovascular disease risk in women with systemic lupus erythematosus.

Authors:  Tim K Tso; Wen-Nan Huang
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

Review 3.  Update on cardiovascular disease in lupus.

Authors:  Laura B Lewandowski; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2016-09       Impact factor: 5.006

4.  Impact of Diabetes Mellitus on the Risk of End-Stage Renal Disease in Patients with Systemic Lupus Erythematosus.

Authors:  Ming-Yan Jiang; Jyh-Chang Hwang; I-Jung Feng
Journal:  Sci Rep       Date:  2018-04-16       Impact factor: 4.379

Review 5.  Interplay of diabetes mellitus and rheumatic diseases amidst the COVID-19 pandemic: influence on the risk of infection, outcomes, and immune responses.

Authors:  Pankti Mehta; Armen Yuri Gasparyan; Olena Zimba; George D Kitas; Marlen Yessirkepov
Journal:  Clin Rheumatol       Date:  2022-09-09       Impact factor: 3.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.